Biofrontera announces conference call to be held on May 20, 2020 to discuss first quarter 2020 financial results
May 12, 2020 11:00 ET
|
Biofrontera AG
Leverkusen, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera Reports Full Year 2019 Financial Results
April 20, 2020 11:06 ET
|
Biofrontera AG
Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera AG enters into exclusive license agreement with Maruho Co., Ltd.
April 20, 2020 04:20 ET
|
Biofrontera AG
Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, has...
Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting
April 16, 2020 10:00 ET
|
Biofrontera AG
Leverkusen, Germany, April 16, 2020 (GLOBE NEWSWIRE) -- The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the Company...
Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz® in Poland with medac GmbH Sp. z o.o.
March 13, 2020 08:00 ET
|
Biofrontera AG
Leverkusen, Germany, March 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with...
Biofrontera provides clinical development updates
February 19, 2020 05:45 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck
January 14, 2020 00:30 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced...
Biofrontera to Participate in Upcoming Investor Conferences
November 22, 2019 11:06 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its...
Biofrontera Files Label Extension for Ameluz® in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck
September 17, 2019 05:45 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has filed a label...
Biofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year 2019 Financial Results
August 14, 2019 05:30 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...